MarketBeat
21 Jun 2026, 14:31 UTC · 2h ago
3 Biotech Firms With Major Potential Catalysts in the Coming Months
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
21 Jun 2026, 14:31 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Vera Therapeutics (VERA) plans to submit a Biologics License Application (BLA) for atacicept by the end of the year, pending Q3 eGFR analysis results. — FDA approval would grant access to a $20-billion market, while a failure or delay would be severely detrimental to a clinical-stage company.
+0.80Krystal Biotech (KRYS) expects top-line results for its KB803 corneal abrasion treatment by the end of this year. — Positive data would provide significant momentum and expand the company's portfolio of approved gene therapies.
+0.60ADMA Biologics (ADMA) is experiencing margin expansion driven by new manufacturing efficiencies and 28% YOY growth in ASCENIV revenue. — Operational efficiency and existing revenue streams provide fundamental stability and growth independent of clinical trial outcomes.
+0.40Continue reading
6 related stories
Search tags
Krystal Biotech's Vyjuvek reported first-quarter revenue of $116 million, a 32% year-over-year increase. — Strong commercial traction for its first approved product validates the company's platform and financial viability.
+0.30Which stocks this story touches
Strong revenue growth from Vyjuvek and positive momentum from upcoming data readouts for new candidates.
Bullish analyst ratings and potential for significant commercial growth following a pending FDA decision on atacicept.
Strong revenue growth, margin expansion, and attractive valuation despite a year-to-date price decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Seeking Alpha
57m ago
